BioNTech SE (BNTX) Evaluates Vaccine Manufacturing Options in Rwanda and Senegal to Improve Long-Term Vaccine Supply

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. ABBV
3. META
4. SPY
5. IBM
6. MU
7. FDX
8. BLZE
9. DFTX
10. NKE

Go back to BioNTech SE (BNTX) Evaluates Vaccine Manufacturing Options in Rwanda and Senegal to Improve Long-Term Vaccine Supply

Joint Communiqué: BioNTech Evaluates mRNA Vaccine Manufacturing Solutions in Rwanda and Senegal to Improve Long-Term Vaccine Supply

August 27, 2021 7:15 AM EDT

BERLIN, GERMANY, August 27, 2021 (GLOBE NEWSWIRE) BioNTech SE (Nasdaq: BNTX, BioNTech or the Company) agreed today to evaluate the establishment of sustainable vaccine manufacturing capabilities in Rwanda and Senegal to support vaccine supply for the Member States of the African Union. Following the invitation of the kENUP Foundation, President Paul Kagame of Rwanda, President Macky Sall of Senegal, and President Ursula von der Leyen of the European... More